Leslie W. Kreis - Nov 4, 2021 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role
Director, 10%+ Owner
Signature
/s/ Leslie W. Kreis, Jr.
Stock symbol
LTRN
Transactions as of
Nov 4, 2021
Transactions value $
$0
Form type
4
Date filed
11/8/2021, 04:23 PM
Previous filing
Aug 17, 2021
Next filing
Mar 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LTRN Common Stock 504K Nov 4, 2021 By Bios Fund I, LP F1, F2, F4
holding LTRN Common Stock 295K Nov 4, 2021 By Bios Fund I QP, LP F1, F2, F4
holding LTRN Common Stock 205K Nov 4, 2021 By Bios Fund II, LP F1, F2, F4
holding LTRN Common Stock 669K Nov 4, 2021 By Bios Fund II QP, LP F1, F2, F4
holding LTRN Common Stock 89.5K Nov 4, 2021 By Bios Fund II NT, LP F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LTRN Stock Option Award $0 +3.2K $0.00 3.2K Nov 4, 2021 Common Stock 3.2K $10.32 By BP Directors, LP F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Mr. Kreis, and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.
F2 Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
F3 In consideration of Mr. Kreis' service as a director of the Issuer, Bios Directors was granted options to purchase 3,200 shares of the Issuer's common stock at the exercise price of $10.32 per share. The options granted will vest in equal monthly increments over a 36 month period commencing on December 4, 2021. Under the Issuer's Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the grant date.
F4 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Remarks:

[none]